INBISTRA

INBISTRA is a strategic consulting firm specialized in the preclinical development of biomedical projects. We work with startups, pharmaceutical companies, investors, and research centers, providing a rigorous and hands-on perspective that combines scientific excellence, strategic thinking, and proprietary AI-powered tools.
We turn scientific discoveries into viable projects with real health impact. We help optimize R&D strategies, support informed decision-making, reduce risks, and maximize asset value before reaching clinical or investment stages.
Our expertise in target identification and disease positioning has enabled the advancement of multiple projects—both small molecules and biologics—to clinical trials. Some have received Fast Track designation by agencies such as the FDA. Together with our international experience across leading research institutions, biotech companies, and Big Pharma, this positions us as trusted partners during critical development phases.
Our work is guided by principles that reflect who we are and how we operate:

•    Operational excellence backed by real-world experience: we have led programs from concept to clinical trials, managed CROs, submitted regulatory filings, and taken responsibility for outcomes. We advise based on practice, not theory.
•    Objective evaluations powered by proprietary AI tools.
•    Global perspective with local insight to navigate strategic differences.
•    Active and meaningful network: we connect clients with scientific hubs, CROs, pharma companies, and academic labs to foster high-value collaborations.
•    Boutique model with genuine commitment: senior-level support focused on building internal capabilities—not dependency.

INBISTRA aims to set a new standard in early-stage biotech consulting: agile, rigorous, and aligned with the real-world challenges of turning science into health solutions.